Related Experiment Video
Updated: May 11, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Motor neuron involvement in multisystem proteinopathy: implications for ALS
Michael Benatar1, Joanne Wuu, Catalina Fernandez
1Department of Neurology, University of Miami, Miami, FL, USA. mbenatar@miami.edu
Objective:
To explore the putative connection between inclusion body myopathy, Paget disease, frontotemporal dementia (IBMPFD) and motor neuron disease (MND).
Methods:
Clinical, genetic, and EMG characterization of 17 patients from 8 IBMPFD families.
Results:
Limb weakness was the most common clinical manifestation (present in 15 patients, median onset age 38 years, range 25-52), with unequivocal evidence of upper motor neuron dysfunction in 3. EMG, abnormal in all 17, was purely neurogenic in 4, purely myopathic in 6, and mixed neurogenic/myopathic in 7. Cognitive/behavioral impairment was detected in at least 8. Mutations in VCP (R155H, R159G, R155C) were identified in 6 families, and in hnRNPA2B1 (D290V) in another family. The genetic cause in the eighth family has not yet been identified.
Conclusion:
Mutations in at least 4 genes may cause IBMPFD, and its phenotypic spectrum extends beyond IBM, Paget disease, and frontotemporal dementia (FTD). Weakness, the most common and disabling manifestation, may be caused by muscle disease or MND. The acronym IBMPFD is, therefore, insufficient to describe disorders due to VCP mutations or other recently identified IBMPFD-associated genes. Instead, we favor the descriptor multisystem proteinopathy (MSP), which encompasses both the extended clinical phenotype and the previously described prominent pathologic feature of protein aggregation in affected tissues. The nomenclature MSP1, MSP2, and MSP3 may be used for VCP-, HNRNPA2B1-, and HNRNPA1-associated disease, respectively. Genetic defects in MSP implicate a range of biological mechanisms including RNA processing and protein homeostasis, both with potential relevance to the pathobiology of more common MNDs such as amyotrophic lateral sclerosis (ALS) and providing an additional link between ALS and FTD.
Insights
Genetic mutations can cause inclusion body myopathy, Paget disease, and frontotemporal dementia (IBMPFD), a condition that also affects motor neurons. A new term, multisystem proteinopathy (MSP), better describes this expanding spectrum of disease.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Inclusion body myopathy, Paget disease, and frontotemporal dementia (IBMPFD) is a rare genetic disorder.
- The clinical spectrum and genetic causes of IBMPFD are not fully understood.
Purpose of the Study:
- To investigate the connection between IBMPFD and motor neuron disease (MND).
- To characterize the clinical and genetic features of patients with IBMPFD.
Main Methods:
- Clinical, genetic, and EMG assessments were performed on 17 patients from 8 IBMPFD families.
- Genetic analysis identified mutations in VCP and hnRNPA2B1 genes.
Main Results:
- Limb weakness was the most common symptom, with onset in adulthood.
- Upper motor neuron dysfunction and cognitive impairment were observed in some patients.
- EMG showed neurogenic, myopathic, or mixed abnormalities.
Conclusions:
- The phenotypic spectrum of IBMPFD is broader than previously recognized, including MND.
- The term multisystem proteinopathy (MSP) is proposed to encompass the diverse clinical features and underlying genetic defects.
- Genetic defects in MSP may provide insights into the pathobiology of common neurodegenerative diseases like ALS and FTD.
More Related Videos
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Multiple Sclerosis l: Introduction
Alterations in Muscle Tone lll
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

